Artificial Insemination (AI) Using Ovulation Induction

By BSc, MSc (embryologist) and BA, MA (fertility counselor).
Last Update: 04/15/2014

The first step toward artificial insemination is undergoing controlled ovarian hyperstimulation, while monitoring the whole process in order to ensure that everything is going well.

The different sections of this article have been assembled into the following table of contents.

What is ovulation induction?

Ovulation induction< is performed by prescribing medicines which contain clomiphene (INN), a.k.a. clomiphene (USAN), or gonadotropins (FSH and LH) taken in low doses from day 2 or 3 of the cycle (it is considered as day 1 the first day of menstruation). They may be sold under different trade names. This process takes usually between 8 and 14 days.

The hormones may be injected either subcutaneously or intramuscularly, depending on the medical guidelines. These guidelines are established according to several factors such as the patient's age, the morphology of the ovaries, the body mass, the hormone analysis, and the response to induction in previous cycles.

Specialists usually adapt the medication and the most adequate doses to each women rather than standardizing the treatment.

Artificial insemination using ovulation induction

Things to consider

A moderate ovulation induction treatment is carried out in order to avoid the development of more follicles than intended and, thus, decrease the risk of multiple births.

The monitoring process is performed by means of periodic transvaginal ultrasounds. Its purpose is to control the number of follicles within each ovary, to schedule the exact insemination date, and to measure the endometrial thickness.

The gynaecologist checks the progress of follicular ripening until the follicles are approximately 18 millimetres in diameter. In this moment, they are considered to be mature enough and that is when the hCG hormone is administered to trigger ovulation.

This allows the exact insemination date to be calculated.

Our editors have made great efforts to create this content for you. By sharing this post, you are helping us to keep ourselves motivated to work even harder.

Authors and contributors

 Neus Ferrando Gilabert
Neus Ferrando Gilabert
BSc, MSc
Embryologist
Bachelor's Degree in Biology from the University of Valencia (UV). Postgraduate Course in Biotechnology of Human Assisted Reproduction from the Miguel Hernández University of Elche (UMH). Experience managing Embryology and Andrology Labs at Centro Médico Manzanera (Logroño, Spain). More information about Neus Ferrando Gilabert
Adapted into english by:
 Sandra Fernández
Sandra Fernández
BA, MA
Fertility Counselor
Bachelor of Arts in Translation and Interpreting (English, Spanish, Catalan, German) from the University of Valencia (UV) and Heriot-Watt University, Riccarton Campus (Edinburgh, UK). Postgraduate Course in Legal Translation from the University of Valencia. Specialist in Medical Translation, with several years of experience in the field of Assisted Reproduction. More information about Sandra Fernández

Find the latest news on assisted reproduction in our channels.